Bone Biologics Corp(BBLG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 7 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BBLG Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Bone Biologics Corp (BBLG), a Healthcare sector company. BBLG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 7 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Bone Biologics Corp reports net income of $-766.0K, free cash flow of $-804.3K. Top institutional holders of BBLG by reported 13-F value include CITADEL ADVISORS, UBS Group AG, Tower Research Capital (TRC), based on the most recent SEC filings. BBLG trades on the Nasdaq exchange and files with the SEC under CIK 1419554. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBLG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bone Biologics Corp directly from SEC EDGAR.
Net Income
Q1 2026
$-766.0K
Free Cash Flow
Q1 2026
$-804.3K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+54.0% YoYOperating Income
+55.3% YoYEPS (Diluted)
+14.8% YoYTotal Assets
+3.3% YoYOp. Cash Flow
+56.8% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.07B +0.0% | $1.07B |
| Net Income | $-4.1M +54.0% | $-8.9M -502.8% | $-1.5M +7.8% | $-1.6M +11.7% | $-1.8M +46.7% | $-3.4M |
| Operating Income | $-4.2M +55.3% | $-9.4M -157.2% | $-3.7M -232.3% | $-1.1M -33.7% | $-825.0K +66.3% | $-2.4M |
| EPS (Diluted) | $-28.96 +14.8% | $-34.01 -9.2% | $-31.15 | — | — | — |
| Total Assets | $3.9M +3.3% | $3.7M -56.0% | $8.5M +27.3% | $6.7M | $0.00 -100.0% | $30.8K |
| Operating Cash Flow | $-4.1M +56.8% | $-9.6M -167.9% | $-3.6M -190.3% | $-1.2M -187.8% | $-426.9K +86.9% | $-3.3M |
AI Insight: BBLG Financial Trends
Pre-revenue biotech burning ~$1M per quarter with equity volatility; no visible path to commercialization.
• Operating cash burn stable at $1M/quarter across all eight quarters; no deterioration or improvement.
• Equity base fluctuated $3M–$7M over two years, peaking Q2 2025 at $7M, now $5M in Q1 2026.
⚠ No revenue disclosed across entire 8-quarter window; development-stage company with no commercial traction yet.
⚠ Q4 2024 net loss doubled to $2M; reverted to $1M baseline afterward—cause and recurrence unclear.
AI Insight: BBLG Ratio Trends
Bone Biologics remains deeply unprofitable; returns deteriorated sharply in Q1 2026 after stabilizing through 2025.
• ROE collapsed to -65.6% in Q1 2026 from -50.9% in Q4 2025; ROA fell to -61.5% from -47.2% in same period.
• ROIC worsened to -69.0% in Q1 2026 versus -54.5% in Q4 2025, reversing modest stabilization seen in Q2–Q3 2025.
• Company has posted negative returns across all profitability metrics for nine consecutive quarters; no path to positive earnings visible.
⚠ Q1 2026 marks the worst quarterly performance since Q4 2024 (-174.7% ROE); deterioration magnitude suggests operational or accounting headwind.
⚠ Absence of operating margin and NPM data limits visibility into cost structure and pricing power—critical for unprofitable biotech.
Get alerted when BBLG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Bone Biologics Corp including:
Top Institutional Holders of BBLG
CITADEL ADVISORS LLC
$684.3K29,752 shUBS Group AG
$5.6K422 shTower Research Capital LLC (TRC)
$4.5K4,126 shSBI Securities Co., Ltd.
$253.00230 shUBS Group AG
$62.0056 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $684.3K | 29,752 |
| UBS Group AG | $5.6K | 422 |
| Tower Research Capital LLC (TRC) | $4.5K | 4,126 |
| SBI Securities Co., Ltd. | $253.00 | 230 |
| UBS Group AG | $62.00 | 56 |
More Healthcare Companies
View all Healthcare →Put BBLG on your watchlist
Track score changes the day Bone Biologics Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BBLG a good stock to buy?
13F Pro's AI-powered analysis of Bone Biologics Corp (BBLG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BBLG are available on the BBLG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BBLG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BBLG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bone Biologics Corp's investment landscape.